Post-marketing surveillance has also examined potential associations with pancreatic cancer, given the pancreatic effects of these medications, though current evidence does not support a causal relationship
The SURMOUNT trials with tirzepatide demonstrated weight loss exceeding 20% at the highest doses, substantially more than what orforglipron has achieved in Phase 3
We work exclusively with trusted, certified sterile pharmacies that follow all applicable state and federal guidelinesbecause your safety and results matter
That's why many people find printable food lists, grocery guides, and meal planners helpful
Deletion of the calcitonin/calcitonin gene-related peptide CT/CGRP gene in a mouse model leads to a higher bone mass, (22) a finding that is supported by a similar phenotype in mice in which the CT receptor is deleted (23) In both model systems, disruption of the CT signaling pathway leads to increased bone formation, a surprising finding that argues for a role of this peptide as an inhibitor of bone formation
In clinical trials, tirzepatide demonstrated reductions in hemoglobin A1c of up to 2.5% and weight loss of approximately 15-21% of body weight at higher doses after 72 weeks of treatment, with results varying by dose and patient population